Vir Biotechnology, INC Form 4 insider transactions

SVF Endurance (Cayman) Ltd, an affiliate of SoftBank Vision Fund, sold 191,854 shares of Vir Biotechnology common stock for a weighted average price of $5.9826.

Vir Biotechnology Director Vicki L. Sato sold 22,000 shares of common stock for approximately $6.00 per share under a pre-arranged 10b5-1 trading plan.

SoftBank-affiliated entities, including SVF Endurance (Cayman) Ltd, reported sales of Vir Biotechnology common stock totaling 189,431 shares under a pre-arranged trading plan.

Affiliates of SoftBank Vision Fund sold over 460,000 shares of Vir Biotechnology common stock in late November 2025, reducing their beneficial ownership.

Vir Biotechnology's EVP & CFO, Jason O'Byrne, sold 6,799 shares of common stock at $5.557 per share to cover tax withholding related to restricted stock unit vesting.

A Vir Biotechnology executive sold 2,385 shares of common stock for $5.16 per share under a pre-arranged trading plan.

Vir Biotechnology's EVP and General Counsel, Vanina de Verneuil, sold 1,365 shares of common stock to cover tax withholding obligations.

Vicki L. Sato, a Director at Vir Biotechnology, Inc., sold 22,000 shares of common stock for a weighted average price of $5.6385 per share pursuant to a pre-arranged trading plan.

SVF Endurance (Cayman) Ltd, an affiliate of SoftBank Vision Fund, reported the sale of 24,553 shares of Vir Biotechnology common stock.

SoftBank affiliate SVF Endurance (Cayman) Ltd sold 113,099 Vir Biotechnology shares in October 2025.

SVF Endurance (Cayman) Ltd, an affiliate of SoftBank Vision Fund, reported the sale of 298,649 shares of Vir Biotechnology, Inc. common stock.

SVF Endurance (Cayman) Ltd, a 10% owner and director, reported sales of Vir Biotechnology common stock totaling 330,210 shares under a Rule 10b5-1 plan.

Affiliates of SoftBank Vision Fund, a 10% owner and director, sold over 29,000 shares of Vir Biotechnology common stock in pre-arranged transactions.

SVF Endurance (Cayman) Ltd, an affiliate of SoftBank Vision Fund, reported sales of Vir Biotechnology common stock totaling 251,360 shares under a pre-arranged trading plan.

SVF Endurance (Cayman) Ltd, a 10% owner of Vir Biotechnology, Inc., reported planned sales of common stock totaling 538,375 shares in early October 2025 under a Rule 10b5-1 trading plan.

Affiliates of SoftBank Vision Fund reported sales of Vir Biotechnology common stock totaling 524,297 shares through a pre-arranged Rule 10b5-1 trading plan.

Vicki L. Sato, a director at Vir Biotechnology, sold 22,000 shares of common stock for a weighted average price of $5.8362 per share under a pre-arranged trading plan.

Vir Biotechnology Director Vicki L. Sato sold 22,000 shares of common stock for approximately $4.99 per share as part of a pre-arranged 10b5-1 trading plan.

Vir Biotechnology Director Vicki L. Sato sold 22,000 shares of common stock for approximately $4.99 per share under a pre-arranged trading plan.

Mark Eisner, Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc., sold a total of 10,382 shares of common stock in two separate transactions in July 2025.

Vicki L. Sato, a Director at Vir Biotechnology, Inc., sold 22,000 shares of common stock on July 1, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Vir Biotechnology Director Robert J. More reported the transfer of 14,027 shares of common stock for no consideration to Alta Partners NextGen Fund I, L.P. in connection with RSU award vesting, impacting both his direct and indirect holdings.

Norbert W. Bischofberger, a Director at Vir Biotechnology, Inc., transferred 10,667 shares of common stock from direct to indirect ownership for tax planning purposes on June 6, 2025.

Vir Biotechnology, Inc. Director Charles Elliott Sigal has acquired 8,000 restricted stock units and 16,000 stock options, increasing his direct beneficial ownership in the company.

Vir Biotechnology, Inc. Director Vicki L. Sato acquired 8,000 restricted stock units and was granted 16,000 stock options, increasing her beneficial ownership in the company.

Vir Biotechnology, Inc. Director Saira Ramasastry acquired 8,000 restricted stock units and 16,000 stock options, signaling increased insider ownership.

Vir Biotechnology, Inc. Director Janet Napolitano reported the acquisition of 8,000 restricted stock units and 16,000 stock options, alongside the sale of 3,200 common shares under a pre-arranged trading plan.

Vir Biotechnology, Inc. Director Robert More has reported the acquisition of 8,000 restricted stock units and 16,000 stock options, signaling increased direct equity interest in the company.

Jeffrey S. Hatfield, a Director at Vir Biotechnology, Inc., has acquired 8,000 restricted stock units and 16,000 stock options, increasing his beneficial ownership in the company.

Vir Biotechnology, Inc. announced that Director Ramy Farid was granted 8,000 restricted stock units and 16,000 stock options, effective May 30, 2025, as part of the company's equity incentive plan.